These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6465106)

  • 61. Safety implications of the over-the-counter availability of H2-antagonists.
    Andersen M; Schou JS
    Drug Saf; 1993 Mar; 8(3):179-85. PubMed ID: 8095787
    [No Abstract]   [Full Text] [Related]  

  • 62. Techniques of postmarketing surveillance. An overview.
    Carson JL; Strom BL
    Med Toxicol; 1986; 1(4):237-46. PubMed ID: 3537618
    [No Abstract]   [Full Text] [Related]  

  • 63. Effect of an antiandrogenic H2 receptor antagonist on hepatic regeneration in rats.
    Kahn D; Svanas GW; Eagon PK; Makowka L; Podesta L; Chapchap P; Starzl TE; Van Thiel DH
    J Lab Clin Med; 1988 Aug; 112(2):232-9. PubMed ID: 3397626
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adverse reactions and interactions with H2-receptor antagonists.
    Penston J; Wormsley KG
    Med Toxicol; 1986; 1(3):192-216. PubMed ID: 2878343
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical relevance of cimetidine drug interactions.
    Shinn AF
    Drug Saf; 1992; 7(4):245-67. PubMed ID: 1524698
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cimetidine postmarket outpatient surveillance program. Interim report on phase I.
    Gifford LM; Aeugle ME; Myerson RM; Tannenbaum PJ
    JAMA; 1980 Apr; 243(15):1532-5. PubMed ID: 7359735
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report.
    Colin Jones DG; Langman MJ; Lawson DH; Vessey MP
    Q J Med; 1985 Mar; 54(215):253-68. PubMed ID: 3991880
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary.
    Humphries TJ; Myerson RM; Gifford LM; Aeugle ME; Josie ME; Wood SL; Tannenbaum PJ
    Am J Gastroenterol; 1984 Aug; 79(8):593-6. PubMed ID: 6465106
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Drug surveillance. Monitoring the side-effects of drugs in the post-marketing phase: cimetidine. II].
    Mariani L; Minora T
    Clin Ter; 1984 Apr; 109(2):109-25. PubMed ID: 6234121
    [No Abstract]   [Full Text] [Related]  

  • 71. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.